Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06691828 · ClinicalTrials.gov registry record · Phase 1
Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
A Phase 1 study, sponsored by Nurix Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06691828 is a Phase 1 study that has completed, run by Nurix Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT06691828, a Phase 1 study, has completed, sponsored by Nurix Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of \[14C\]-NX-5948. Period 1 will analyze PD (pharmacodynamics) and exploratory biomarkers. Period 2 will analyze total radioactivity and metabolite profiling.
Interventions
- DRUG NX-5948
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2024-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06691828
The ClinicalTrials.gov registry entry for NCT06691828 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nurix Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NX-5948 is the first listed.
NCT06691828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06691828 about?
NCT06691828 is a clinical study titled "Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948". This is a Phase 1, 2-period, open-label, single-dose, fixed-sequence study to assess the absolute bioavailability, absorption, metabolism, excretion, and mass balance of \[14C\]-NX-5948. Period 1 will analyze PD (pharmacodynamics) and exploratory biomarkers. Period 2 will analyze total radioactivity...
What is the current status of trial NCT06691828?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-11-01. Estimated completion is 2024-12-05.
What interventions are being tested in trial NCT06691828?
The interventions under investigation include: NX-5948 (DRUG).
Who is sponsoring clinical trial NCT06691828?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.